Search research articles
Contact Us
Filters
Showing results (111-120 of 158) with videos related to
Page
of 16
Sort By:
JACC. Cardiovascular Imaging
|
September 7, 2023
Cardiac Amyloid Quantification Using <sup>124</sup>I-Evuzamitide (<sup>124</sup>I-P5+14) Versus <sup>18</sup>F-Florbetapir: A Pilot PET/CT Study
Olivier F Clerc, Sarah A M Cuddy, Matthew Robertson, et al.
American Journal of Hematology
|
July 27, 2005
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004
Morie A Gertz, Ray Comenzo, Rodney H Falk, et al.
EMBO Molecular Medicine
|
October 17, 2014
Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity
Jian Guan, Shikha Mishra, Yiling Qiu, et al.
EMBO Molecular Medicine
|
May 6, 2015
Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity
Jian Guan, Shikha Mishra, Yiling Qiu, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology
|
August 11, 2024
Quantitative <sup>99m</sup>Tc-pyrophosphate myocardial uptake: Changes on transthyretin stabilization therapy
Shilpa Vijayakumar, Ardel Romero Pabon, Olivier F Clerc, et al.
European Heart Journal. Cardiovascular Imaging
|
December 8, 2025
Evaluating natural history and treatment response in cardiac amyloidosis: the evolving role of multimodality imaging
Amely Walser, Christoph Gräni, Simon F Stämpfli, et al.
American Heart Journal
|
August 11, 2012
Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS)
Frederick L Ruberg, Mathew S Maurer, Daniel P Judge, et al.
Clinical Lymphoma
|
April 4, 2003
Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis
David C Seldin, Elie B Choufani, Laura M Dember, et al.
JAMA Cardiology
|
July 27, 2018
Geographic Disparities in Reported US Amyloidosis Mortality From 1979 to 2015: Potential Underdetection of Cardiac Amyloidosis
Kevin M Alexander, John Orav, Avinainder Singh, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
September 5, 2020
Absolute Quantitation of Cardiac <sup>99m</sup>Tc-Pyrophosphate Using Cadmium-Zinc-Telluride-Based SPECT/CT
Sharmila Dorbala, Mi-Ae Park, Sarah Cuddy, et al.
Page
of 16
Search research articles
Search
Showing results (111-120 of 158) with videos related to
Sort By:
Page
of 16
JACC. Cardiovascular Imaging
|
September 7, 2023
Cardiac Amyloid Quantification Using <sup>124</sup>I-Evuzamitide (<sup>124</sup>I-P5+14) Versus <sup>18</sup>F-Florbetapir: A Pilot PET/CT Study
Olivier F Clerc, Sarah A M Cuddy, Matthew Robertson, et al.
American Journal of Hematology
|
July 27, 2005
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004
Morie A Gertz, Ray Comenzo, Rodney H Falk, et al.
EMBO Molecular Medicine
|
October 17, 2014
Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity
Jian Guan, Shikha Mishra, Yiling Qiu, et al.
EMBO Molecular Medicine
|
May 6, 2015
Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity
Jian Guan, Shikha Mishra, Yiling Qiu, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology
|
August 11, 2024
Quantitative <sup>99m</sup>Tc-pyrophosphate myocardial uptake: Changes on transthyretin stabilization therapy
Shilpa Vijayakumar, Ardel Romero Pabon, Olivier F Clerc, et al.
European Heart Journal. Cardiovascular Imaging
|
December 8, 2025
Evaluating natural history and treatment response in cardiac amyloidosis: the evolving role of multimodality imaging
Amely Walser, Christoph Gräni, Simon F Stämpfli, et al.
American Heart Journal
|
August 11, 2012
Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS)
Frederick L Ruberg, Mathew S Maurer, Daniel P Judge, et al.
Clinical Lymphoma
|
April 4, 2003
Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis
David C Seldin, Elie B Choufani, Laura M Dember, et al.
JAMA Cardiology
|
July 27, 2018
Geographic Disparities in Reported US Amyloidosis Mortality From 1979 to 2015: Potential Underdetection of Cardiac Amyloidosis
Kevin M Alexander, John Orav, Avinainder Singh, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
September 5, 2020
Absolute Quantitation of Cardiac <sup>99m</sup>Tc-Pyrophosphate Using Cadmium-Zinc-Telluride-Based SPECT/CT
Sharmila Dorbala, Mi-Ae Park, Sarah Cuddy, et al.
Page
of 16